All In Biotech

Drug Trial Radar · NCT07178730

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 765 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

765

Planned (sponsor's estimate)

Start

Aug 30, 2026

Primary completion

Mar 31, 2033

Study completion Mar 31, 2033

Sponsor

Lead sponsor
Women's Cancer Study Group GmbHAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Gilead Sciences
First posted
Sep 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TNBC is a heterogeneous disease with distinct pathological, genetic, and clinical features among subtypes. Treatment results for high-risk primary TNBC remain poor compared to other breast cancer subtypes. Preoperative chemotherapy is the standard of care for patients with stage II or III primary TNBC. Multiple lines of clinical evidence demonstrate that TNBC patients who achieve a pCR to NACT, (ypT0/is ypN0), have an excellent long-term prognosis. A meta-analysis of individual patient data confirmed a strong association of pCR after NACT with improved long-term event-free survival (EFS, hazard ratio \[HR\] 0.24) and overall survival (OS, HR 0.16) benefit. Taxane- and anthracycline-based neoadjuvant regimens generally result in pCR rates between 25-50% \[REFs\], whereas the addition of platinum increases pCR rates to approximately 50-55%. The KEYNOTE-522 trial has demonstrated that the addition of the immune-checkpoint inhibitor PEM to anthracycline- (AC), taxane- and platinum-based NACT resulted in a significant increase in pCR rates to nearly 65%, associated with a significant reduction of recurrences (EFS, HR 0.65 at 5 years) and improvement of OS (HR 0.66). Based on these results, the KEYNOTE-522 regimen has been approved by the FDA and EMA and has become the standard of care for patients with stage II or III TNBC. Despite this significant progress, two major questions remain unresolved which will be investigated in the ADAPT-TN-IV trial: 1. Do all patients require the full 6 months of NACT as per KEYNOTE-522 or is there a subgroup of patients who are sufficiently treated with 12 weeks of NACT plus PEM? 2. Can incorporation of ADCs into the KEYNOTE-522 regimen improve response and outcomes in patients without an optimal early response? The outcome of patients with residual disease after 24 weeks of NACT and PEM remains suboptimal and there is an urgent need for more effective strategies. ADCs such as SG have demonstrated superior efficacy compared to standard chemotherapy in metastatic TNBC, resulting in substantially higher response rates and improved progression-free (PFS) and OS. Combination studies of ADCs and immunotherapy in metastatic TNBC have demonstrated significant activity, suggesting possible synergistic activity It is therefore a logical next step to investigate, whether the incorporation of SG in the NACT regimen can improve pCR rates and EFS results in patients who have residual clinical disease after 12 weeks of NACT with CARBO/PAC + PEM.

Conditions

  • Breast Cancer
  • Triple-negative Breast Cancer

Interventions

  • Sacituzumab govitecanDrug

    SG is administered at 10 mg/kg as an intravenous (i.v.) infusion on Days 1 and 8 of a 21-day cycle. The dose of SG will be calculated based on actual weight at randomization (using weight obtained either at enrolment or on Cycle 1 Day 1) and remains constant throughout the study, unless there is a \> 10% change in body weight from baseline. Modifications to the study drug doses administered should be made for a \> 10% change in body weight from baseline and according to local and regional prescribing standards. Dose modifications for changes in body weight \< 10% may be made according to local institutional guidelines. SG is administered via i.v. infusion as described below with additional information available in the current version of the SmPC.

  • Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]Drug

    Pembrolizumab 200 mg will be administered as a 30-minute i.v. infusion every 3 weeks.

  • SoC ChemotherapyDrug

    Standard of care chemotherapy as per common treatment guidelines and recommendations

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort I: 3-year event-free survival (EFS)Time frame: EFS 3 years
  2. Cohort II: superiority of neoadjuvant treatment with SG+PEM vs. SoC with regards to event-free survival (EFS)Time frame: EFS 3 years
  3. Cohort II: superiority of neoadjuvant treatment with SG+PEM vs. SoC with regards to pathological complete response (pCR) ratesTime frame: EFS 3 years

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • University Medical Center Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie

    Hamburg, Germany

  • SLK-Kliniken Heilbronn GmbH, Klinik für Gynäkologie und Geburtshilfe

    Heilbronn, Baden-Wurttemberg, Germany

  • GRN Gesundheitszentren Rhein-Neckar gGmbH, Brustzentrum Weinheim

    Weinheim, Baden-Wurttemberg, Germany

  • Universitaetsklinikum Augsburg, Klinik für Frauenheilkunde und Geburtsmedizin

    Augsburg, Bavaria, Germany

  • Klinikum der Universitaet Muenchen AöR, Frauenheilkunde und Geburtshilfe

    München, Bavaria, Germany

  • Klinikum der Technischen Universitaet Muenchen (TUM Klinikum), Brustzentrum

    München, Bavaria, Germany

  • Caritas-Krankenhaus St. Josef, Frauenheilkunde und Geburtshilfe

    Regensburg, Bavaria, Germany

  • Haematologisch Onkologische Schwerpunktpraxis

    Würzburg, Bavaria, Germany

  • Medical University Of Lausitz Carl Thiem, Frauenklinik

    Cottbus, Brandenburg, Germany

  • Gesundheitszentrum Wetterau gGmbH, Gynäkologische Ambulanz

    Bad Nauheim, Hesse, Germany

  • Klinikum Kassel GmbH, Klinik für Frauenheilkunde und Geburtshilfe

    Kassel, Hesse, Germany

  • Gemeinschaftspraxis Frauenärzte am Bahnhofsplatz

    Hildesheim, Lower Saxony, Germany

  • Universitaetsklinikum Aachen AöR, Gynäkologie und Geburtsmedizin

    Aachen, North Rhine-Westphalia, Germany

  • Universitaetsklinikum Bonn AöR, Senologie

    Bonn, North Rhine-Westphalia, Germany

  • University Hospital Cologne AöR, Brustkrebszentrum

    Cologne, North Rhine-Westphalia, Germany

  • Klinikum Dortmund gGmbH, Frauenklinik Dortmund

    Dortmund, North Rhine-Westphalia, Germany

  • St.-Antonius-Hospital gGmbH, Klinik für Hämatologie und Onkologie

    Eschweiler, North Rhine-Westphalia, Germany

  • Universitaetsklinikum Essen AöR Klinik für Frauenheilkunde und Geburtshilfe

    Essen, North Rhine-Westphalia, Germany

  • Onkodok GmbH Onkologische Gemeinschaftspraxis

    Gütersloh, North Rhine-Westphalia, Germany

  • St. Barbara-Klinik Hamm GmbH, Brustzentrum

    Hamm, North Rhine-Westphalia, Germany

  • Brustzentrum Rhein-Ruhr Servicegesellschaft mbH

    Mönchengladbach, North Rhine-Westphalia, Germany

  • St. Franziskus-Hospital GmbH, MVZ MediaVita

    Münster, North Rhine-Westphalia, Germany

  • MKS St. Paulus GmbH, Märkisches Brustzentrum

    Schwerte, North Rhine-Westphalia, Germany

  • Praxisnetz Hämatologie / internistische Onkologie

    Troisdorf, North Rhine-Westphalia, Germany

  • Marien-Hospital Witten, Brustzentrum

    Witten, North Rhine-Westphalia, Germany

  • Klinikum Obergoeltzsch Rodewisch Frauenklinik / Brustzentrum

    Rodewisch, Saxony, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.